Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Chemomab Therapeutics Ltd ADR (NQ: CMMB ) 1.470 -0.010 (-0.68%) Streaming Delayed Price Updated: 3:59 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Chemomab Therapeutics Ltd ADR Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update October 30, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024 October 15, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Present at October 2024 Investor Conferences October 01, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Present at September 2024 Investor Conferences August 28, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update August 21, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update August 12, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces Closing of $10 Million Private Placement July 30, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement July 26, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces $10 Million Private Placement July 25, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis July 25, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis June 18, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference June 06, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Participate in Upcoming Scientific Conferences May 17, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule May 08, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference May 02, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update April 24, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis April 18, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 April 02, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis March 25, 2024 From Chemomab Therapeutics Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
